WHO ICTRP trial
A clinical trial to explore the potential of ondansetron for treating…
ISRCTN51996779 · International Standard Randomised Controlled Trial Number (ISRCTN) · Recruiting
Key facts
| Trial ID | ISRCTN51996779 |
|---|---|
| Public title | A clinical trial to explore the potential of ondansetron for treating hallucinations in people with Parkinson’s disease |
| Scientific title | Trial of Ondansetron as a Parkinson’s HAllucinations Treatment |
| Primary sponsor | PRIMENT CTU |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase II |
| Countries | England;United Kingdom;Wales |
| Conditions | Parkinson's hallucinations Nervous System Diseases Parkinson disease |
| Interventions | The intervention will consist of flexible dosing of ondansetron/placebo (8-24mg/day) as a treatment for Parkinson’s hallucinations, with a 12-week primary outcome and follow-up to 24 weeks. The treatment dose will increase from a single… |
| Registration date | May 2, 2020 |
| Target size | 216 |
| Secondary IDs | 2019-003962-41;NCT04167813;17/0909, IRAS 266504 |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: